Endo removes Opana ER opioid from the market

05:27 EDT 18 Aug 2017 | Generics and Biosimilars Initiative

The US Food and Drug Administration (FDA) requested that Endo International plc (Endo) remove its opioid medication Opana ER from the market, due to concerns over the ‘public health consequences of abuse’.

Original Article: Endo removes Opana ER opioid from the market


More From BioPortfolio on "Endo removes Opana ER opioid from the market"

Quick Search


Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...